Immediate Management of Atrial Fibrillation with Hemodynamic Compromise

Clinical Presentation and Rationale for Cardioversion

The American College of Cardiology recommends urgent direct-current cardioversion in patients with acute coronary syndromes or heart failure presenting with new-onset atrial fibrillation and hemodynamic instability or inadequate rate control, as seen in patients with severe left ventricular dysfunction (LVEF 35%) and signs of acute hemodynamic compromise 1
Patients with new-onset atrial fibrillation and rapid ventricular response (HR 152 bpm) in the setting of severe left ventricular dysfunction (LVEF 35%) are at high risk of acute hemodynamic compromise, and cardioversion is the most appropriate next step in management 1
Severe systolic dysfunction, as indicated by an LVEF of 35%, significantly limits cardiac reserve and tolerance of tachyarrhythmias, making cardioversion a necessary intervention 2
Evidence of decompensation, such as 2+ bilateral lower extremity edema, suggests worsening heart failure and necessitates prompt treatment with cardioversion 3
Rapid ventricular rate, as seen in this patient with a heart rate of 152 bpm, compromises cardiac output through shortened diastolic filling time and requires immediate attention with cardioversion 4

The American College of Cardiology/American Heart Association guidelines state that synchronous cardioversion may be accomplished at relatively low energies (50-100 J biphasic) in the acutely ill patient with heart failure, making it an appropriate treatment option for this patient 2
The use of 120 J for cardioversion represents appropriate energy delivery, according to the American College of Cardiology/American Heart Association guidelines 2

After successful cardioversion, initiation of oral beta-blocker (metoprolol tartrate 25 mg every 6 hours initially, titrating to 100 mg twice daily) is recommended for rate control and mortality benefit in heart failure 3
Starting or optimizing heart failure medications, such as ACE inhibitor/ARB and aldosterone antagonist, is crucial in patients with heart failure, as long as creatinine and potassium levels are within acceptable limits 3
Anticoagulation with DOACs is preferred over warfarin in heart failure patients with a CHA₂DS₂-VASc score ≥2, and should be initiated after cardioversion 6, 1
Consideration of amiodarone is recommended if atrial fibrillation recurs despite beta-blocker therapy, as it is the safest antiarrhythmic in structural heart disease 7, 6

Delaying cardioversion to attempt pharmacologic rate control in hemodynamically compromised patients with severe LV dysfunction is not recommended, as it can worsen outcomes 1, 2
The use of calcium channel blockers (diltiazem, verapamil) is contraindicated in patients with LVEF ≤40% due to negative inotropic effects, and should be avoided in this patient population 1
IV beta-blockers should not be used as first-line treatment in acute decompensated heart failure with signs of hypoperfusion, and should be reserved for hemodynamically stable patients or after cardioversion 1
Assuming rate control alone will resolve symptoms in new-onset atrial fibrillation with severe LV dysfunction is not sufficient, as rhythm control via cardioversion provides superior acute hemodynamic benefit 1, 2